keyword
MENU ▼
Read by QxMD icon Read
search

Non hodgkin's lymphoma

keyword
https://www.readbyqxmd.com/read/27906436/iliac-crest-bone-graft-a-23-years-hystory-of-infection-at-donor-site-in-vertebral-arthrodesis-and-a-review-of-current-bone-substitutes
#1
L Babbi, G Barbanti-Brodano, A Gasbarrini, S Boriani
OBJECTIVE: This is an exemplary case report underlining a relevant morbidity which could be associated to the use of autologous iliac crest bone graft (ICBG) for spine fusion. CASE REPORT: Starting from 1990, a 25-years-old woman underwent two subsequent surgical treatments for non-Hodgkin lymphoma vertebral localizations. In the second surgery, arthrodesis was obtained with autograft through right posterior iliac crest osteotomy. During the chemotherapy treatment following the surgery, the patient suffered from infection at posterior iliac crest scar, the site of previous graft, caused by methicillin-resistant Staphylococcus aureus...
November 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27905841/cell-delivered-entry-inhibitors-for-hiv-1-ccr5-downregulation-and-blocking-virus-membrane-fusion-in-defending-the-host-cell-population
#2
Geoff Symonds, Jeffrey S Bartlett, Hans-Peter Kiem, Marlene Tsie, Louis Breton
HIV-1 infection requires the presence of the CD4 receptor on the target cell surface and a coreceptor, predominantly CC-chemokine receptor 5 (CCR5). It has been shown that individuals who are homozygous for a defective CCR5 gene are protected from HIV-1 infection. A novel self-inactivating lentiviral vector LVsh5/C46 (Cal-1) has been engineered to block HIV-1 infection with two viral entry inhibitors, conferring resistance to HIV-1 infection from both CCR5 and CXCR4 tropic strains. Cal-1 encodes a short hairpin RNA (sh5) to downregulate CCR5 and C46, an HIV-1 fusion inhibitor...
December 2016: AIDS Patient Care and STDs
https://www.readbyqxmd.com/read/27905485/b-and-t-lymphocyte-number-and-function-in-hiv-hiv-lymphoma-patients-treated-with-high-dose-chemotherapy-and-autologous-bone-marrow-transplantation
#3
Diego Bertoli, Alessandro Re, Marco Chiarini, Alessandra Sottini, Federico Serana, Viviana Giustini, Aldo M Roccaro, Chiara Cattaneo, Luigi Caimi, Giuseppe Rossi, Luisa Imberti
Combination of anti-retroviral therapy, high-dose chemotherapy (HCT) and autologous stem cell transplantation (ASCT) has led to an improved survival of HIV(+) non-Hodgkin lymphoma (NHL) patients. We compared T- and B-cell subset recovery and related capability to respond to in-vitro stimulation, as well as T-cell repertoire modifications of HIV(+) and HIV(-) NHL patients undergoing HCT and ASCT as first-line consolidation or salvage treatment, using sequential blood samples obtained before and at 3, 6, 12 and 24 months after ASCT...
December 1, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27905003/new-agents-in-hsc-mobilization
#4
REVIEW
Mélanie J Domingues, Susan K Nilsson, Benjamin Cao
Mobilized peripheral blood (PB) is the most common source of hematopoietic stem cells (HSC) for autologous transplantation. Granulocyte colony stimulating factor (G-CSF) is the most commonly used mobilization agent, yet despite its widespread use, a considerable number of patients still fail to mobilize. Recently, a greater understanding of the interactions that regulate HSC homeostasis in the bone marrow (BM) microenvironment has enabled the development of new molecules that mobilize HSC through specific inhibition, modulation or perturbation of these interactions...
November 30, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27904766/the-role-of-pim1-in-the-ibrutinib-resistant-abc-subtype-of-diffuse-large-b-cell-lymphoma
#5
Hsu-Ping Kuo, Scott A Ezell, Sidney Hsieh, Karl J Schweighofer, Leo Wk Cheung, Shiquan Wu, Mutiah Apatira, Mint Sirisawad, Karl Eckert, Yu Liang, Jeff Hsu, Chun-Te Chen, Darrin Beaupre, Betty Y Chang
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous lymphoma and the most common subtype of non-Hodgkin lymphoma, accounting for roughly 30% of newly diagnosed cases in the United States. DLBCL can be separated into the activated B cell-like (ABC) and germinal center B cell-like (GCB) subtypes, with distinct gene expression profiles, oncogenic aberrations, and clinical outcomes. ABC-DLBCL is characterized by chronically active B-cell receptor (BCR) signaling that can be modulated by Bruton's tyrosine kinase (BTK) activity...
2016: American Journal of Cancer Research
https://www.readbyqxmd.com/read/27904443/prognosis-estimation-under-the-light-of-metabolic-tumor-parameters-on-initial-fdg-pet-ct-in-patients-with-primary-extranodal-lymphoma
#6
Kursat Okuyucu, Sukru Ozaydın, Engin Alagoz, Gokhan Ozgur, Semra Ince, Fahrettin Guven Oysul, Ozlem Ozmen, Murat Tuncel, Mustafa Ozturk, Nuri Arslan
BACKGROUND: Non-Hodgkin's lymphomas arising from the tissues other than primary lymphatic organs are named primary extranodal lymphoma. Most of the studies evaluated metabolic tumor parameters in different organs and histopathologic variants of this disease generally for treatment response. We aimed to evaluate the prognostic value of metabolic tumor parameters derived from initial FDG-PET/CT in patients with a medley of primary extranodal lymphoma in this study. PATIENTS AND METHODS: There were 67 patients with primary extranodal lymphoma for whom FDG-PET/CT was requested for primary staging...
December 1, 2016: Radiology and Oncology
https://www.readbyqxmd.com/read/27900638/bendamustine-plus-rituximab-for-previously-untreated-patients-with-indolent-b-cell-non-hodgkin-lymphoma-or-mantle-cell-lymphoma-a-multicenter-phase-ii-clinical-trial-in-japan
#7
Michinori Ogura, Kenichi Ishizawa, Dai Maruyama, Naokuni Uike, Kiyoshi Ando, Koji Izutsu, Yasuhito Terui, Yoshitaka Imaizumi, Kunihiro Tsukasaki, Kenshi Suzuki, Tohru Izumi, Kensuke Usuki, Tomohiro Kinoshita, Masafumi Taniwaki, Nobuhiko Uoshima, Junji Suzumiya, Mitsutoshi Kurosawa, Hirokazu Nagai, Toshiki Uchida, Noriko Fukuhara, Ilseung Choi, Ken Ohmachi, Go Yamamoto, Kensei Tobinai
A Phase II, multicenter clinical trial of bendamustine plus rituximab (BR) regimen was conducted in previously untreated patients with high-tumor-burden indolent B-cell non-Hodgkin lymphoma (B-NHL) and previously untreated elderly patients with mantle cell lymphoma (MCL) in Japan. Bendamustine 90 mg/m(2)/day on days 1 and 2, as well as rituximab 375 mg/m(2) on day 1 were administered intravenously up to six cycles. The primary endpoint was the complete response (CR) rate as assessed by the International Workshop Response Criteria (1999)...
November 29, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27900446/health-related-quality-of-life-and-symptoms-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-treated-in-the-phase-iii-gadolin-study-with-obinutuzumab-plus-bendamustine-versus-bendamustine-alone
#8
Bruce D Cheson, Peter C Trask, John G Gribben, Natalie Dimier, Eva Kimby, Pieternella J Lugtenburg, Catherine Thieblemont, Elisabeth Wassner-Fritsch, Aino Launonen, Laurie H Sehn
We present health-related quality of life (HRQoL) data from GADOLIN, comparing bendamustine (B) alone or combined with obinutuzumab (G-B) in rituximab-refractory indolent non-Hodgkin lymphoma patients. The Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) questionnaire was administered on day 1 of cycles 1, 3, and 5 during treatment, at end of induction (EOI), bi-monthly for 2 years during maintenance/follow-up, and annually during extended follow-up until progression/death. Time to first ≥6-point worsening from baseline in the FACT-Lym trial outcome index (TOI) was estimated...
November 30, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27897234/association-between-dioxin-and-cancer-incidence-and-mortality-a-meta-analysis
#9
Jinming Xu, Yao Ye, Fang Huang, Hanwen Chen, Han Wu, Jian Huang, Jian Hu, Dajing Xia, Yihua Wu
The objective of the present study was to systematically assess the association between dioxin/2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and cancer incidence and mortality. Systematic literature searches were conducted until July 2015 in Pubmed, Embase and Cochrane library to identify relevant studies. A random-effects model was applied to estimate the pooled odds ratio (OR), risk ratio (RR), standard incidence ratio (SIR) or standard mortality ratio (SMR) for cancer incidence or mortality. In addition, dose-response, meta-regression, subgroup, and publication bias analyses were conducted...
November 29, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27896915/evaluation-of-maternal-and-perinatal-characteristics-on-childhood-lymphoma-risk-a-population-based-case-control-study
#10
Erin C Peckham-Gregory, Heather E Danysh, Austin L Brown, Olive Eckstein, Amanda Grimes, Rikhia Chakraborty, Joseph Lubega, Kenneth L McClain, Carl E Allen, Michael E Scheurer, Philip J Lupo
BACKGROUND: Lymphoma is one of the most common pediatric malignancies; however, there are few well-established risk factors. Therefore, we investigated if maternal and perinatal characteristics influenced the risk of childhood lymphoma. PROCEDURE: Information on cases (n = 374) diagnosed with lymphoma and born in Texas for the period 1995-2011 was obtained from the Texas Cancer Registry. Birth certificate controls were randomly selected at a ratio of 10 controls per 1 case for the same period of 1995-2011...
November 28, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27896571/erratum-to-japanese-phase-ii-study-of-rituximab-maintenance-for-untreated-indolent-b-cell-non-hodgkin-lymphoma-with-high-tumor-burden
#11
Tadahiko Igarashi, Michinori Ogura, Kuniaki Itoh, Masafumi Taniwaki, Kiyoshi Ando, Yoshiaki Kuroda, Kazuhito Yamamoto, Naokuni Uike, Akihiro Tomita, Hirokazu Nagai, Mitsutoshi Kurosawa, Shigeo Mori, Shigeru Nawano, Takashi Terauchi, Yasuo Ohashi, Kensei Tobinai
No abstract text is available yet for this article.
November 28, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27895762/primary-renal-lymphoma-a-case-report-and-literature-review
#12
Xiaodong Chen, Danfei Hu, Laifu Fang, Yichen Chen, Xiaohang Che, Jin Tao, Guobin Weng, Xiaolei Ye
Primary renal lymphoma (PRL) is a rare disease, with no more than 70 cases reported in the literature. The present study reports the case of a 70-year-old woman with PRL. The patient was asymptomatic, however, a mass on the right kidney was identified incidentally during routine physical examination. Computed tomography revealed a mass in the right kidney that was 3.6 cm in diameter. Subsequently, right nephrectomy was performed. The histological evaluation of the nephrectomy specimen showed diffuse large B-cell non-Hodgkin's lymphoma...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27893746/mast-cells-are-abundant-in-primary-cutaneous-t-cell-lymphomas-results-from-a-computer-aided-quantitative-immunohistological-study
#13
Johanna Eder, Radu Rogojanu, Waltraud Jerney, Friedrich Erhart, Alexander Dohnal, Melitta Kitzwögerer, Georg Steiner, Julia Moser, Franz Trautinger
BACKGROUND: Mast cells (MC) are bone marrow derived haematopoetic cells playing a crucial role not only in immune response but also in the tumor microenvironment with protumorigenic and antitumorigenic functions. The role of MC in primary cutaneous T-cell lymphomas (CTCL), a heterogeneous group of non-Hodgkin lymphomas with initial presentation in the skin, is largely unknown. OBJECTIVE: To gain more accurate information about presence, number, distribution and state of activation (degranulated vs...
2016: PloS One
https://www.readbyqxmd.com/read/27892948/long-term-outcomes-after-thiotepa-based-high-dose-therapy-hdt-and-autologous-hematopoietic-cell-transplantation-auto-hct-in-non-hodgkin-lymphoma-nhl
#14
N Shah, S Rauenzahn, L Veltri, S Wen, M Craig, M Hamadani, A S Kanate, A Cumpston
No abstract text is available yet for this article.
November 28, 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27892666/mantle-cell-lymphoma-a-north-indian-tertiary-care-centre-experience
#15
Krushna Das Chandan, Gogia Ajay, Kumar Lalit, Sharma Atul, Chand Sharma Mehar, Ranjan Mallick Saumya
Background: Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin’s lymphoma, with a pathognomonic chromosomal translocation t (11;14). Prognosis is uniformly dismal but there is a paucity of information on MCL from India. Materials and methods: We retrospectively analysed clinicopathological information on all treated patients with MCL at our centre. STATA 14.0 was used for analysis. Survival was assessed by Kaplan-Meier analysis and the Cox’s proportional hazards method. Statistical significance was defined as a P value of < 0...
January 10, 2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/27890995/endotracheobronchial-lymphoma-two-unusual-case-reports-and-review-of-article
#16
Trilok Chand, Avdhesh Bansal, Harsh Dua, Kapil Sharma
The tracheobronchial origin of non-Hodgkin's lymphoma (NHL) is a very rare presentation, and there are only a few case reports of primary tracheal or endobronchial NHL. We have two cases of primary tracheobronchial NHL; one case was incidentally diagnosed as anaplastic large cell lymphoma of endobronchial origin when a comprehensive workup and surgery were carried out for an endobronchial aspergilloma which was actually sitting on top of lymphoma. The second patient was a case of myelodysplastic syndrome who presented with acute respiratory distress; on thorough workup, he was found to have endotracheal B-cell lymphoma...
November 2016: Lung India: Official Organ of Indian Chest Society
https://www.readbyqxmd.com/read/27890383/-autoimmune-and-inflammatory-disorders-associated-with-lymphoid-hematological-malignancies
#17
E Grignano, A Mekinian, V Jachiet, P Coppo, O Fain
In this literature review, we reported autoimmune and inflammatory disorders associated with lymphoid hematological malignancies, including non-Hodgkin's lymphoma, Hodgkin's lymphoma and chronic lymphocytic leukemia. The different types of systemic involvement are classified by affected organ. We listed in this review the joint diseases, skin, neurologic, hematologic, renal, and vasculitis. We tried to determine whether there is a correlation between each autoimmune manifestation and a specific type of lymphoma or a particular feature that may support a paraneoplastic origin, if there is an impact on the prognosis of the hematological malignancy, and finally, we identified the different therapeutic strategies used in the literature...
November 24, 2016: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/27888882/the-challenge-of-primary-central-nervous-system-lymphoma
#18
REVIEW
Julia Carnevale, James L Rubenstein
Primary central nervous system (CNS) lymphoma is a challenging subtypes of aggressive non-Hodgkin lymphoma. Emerging clinical data suggest that optimized outcomes are achieved with dose-intensive CNS-penetrant chemotherapy and avoiding whole brain radiotherapy. Anti-CD20 antibody-based immunotherapy as a component of high-dose methotrexate-based induction programs may contribute to improved outcomes. An accumulation of insights into the molecular and cellular basis of disease pathogenesis is providing a foundation for the generation of molecular tools to facilitate diagnosis as well as a roadmap for integration of targeted therapy within the developing therapeutic armamentarium for this challenging brain tumor...
December 2016: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/27888878/the-spectrum-of-double-hit-lymphomas
#19
REVIEW
Jeremy S Abramson
Double-hit lymphomas (DHLs) characterize a unique subset of B-cell non-Hodgkin lymphomas. DHL typically presents in older adults with high-risk clinical features. This entity carries a significantly inferior prognosis compared with typical cases of diffuse large B-cell lymphoma; however, emerging literature can identify discrete clinical features within DHL that are associated with a favorable prognosis. Emerging literature is also demonstrating that intensive upfront treatment strategies may improve outcome...
December 2016: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/27888799/new-bipyridine-gold-iii-dithiocarbamate-containing-complexes-exerted-a-potent-anticancer-activity-against-cisplatin-resistant-cancer-cells-independent-of-p53-status
#20
Muhammad Altaf, Muhammad Monim-Ul-Mehboob, Abdel-Nasser Kawde, Giuseppe Corona, Roberto Larcher, Marcia Ogasawara, Naike Casagrande, Marta Celegato, Cinzia Borghese, Zahid H Siddik, Donatella Aldinucci, Anvarhusein A Isab
We synthesized, characterized and tested in a panel of cancer cell lines, nine new bipyridine gold(III) dithiocarbamate-containing complexes. In vitro studies demonstrated that compounds 1, 2, 4, 5, 7 and 8 were the most cytotoxic in prostate, breast, ovarian cancer cell lines and in Hodgkin lymphoma cells with IC50 values lower than the reference drug cisplatin. The most active compound 1 was more active than cisplatin in ovarian (A2780cis and 2780CP-16) and breast cancer cisplatin-resistant cells. Compound 1 determined an alteration of the cellular redox homeostasis leading to increased ROS levels, a decrease in the mitochondrial membrane potential, cytochrome-c release from the mitochondria and activation of caspases 9 and 3...
November 18, 2016: Oncotarget
keyword
keyword
30166
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"